2. Academic Validation
  3. Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis

Long lasting control of viral rebound with a new drug ABX464 targeting Rev - mediated viral RNA biogenesis

  • Retrovirology. 2015 Apr 9;12:30. doi: 10.1186/s12977-015-0159-3.
Noëlie Campos 1,  Renier Myburgh 2,  Aude Garcel 3,  Audrey Vautrin 4,  Laure Lapasset 5,  Erika Schläpfer Nadal 6,  Florence Mahuteau-Betzer 7,  Romain Najman 8,  Pauline Fornarelli 9,  Katjana Tantale 10,  Eugénia Basyuk 11,  Martial Séveno 12,  Julian P Venables 13,  Bernard Pau 14,  Edouard Bertrand 15,  Mark A Wainberg 16,  Roberto F Speck 17,  Didier Scherrer 18,  Jamal Tazi 19
Affiliations

Affiliations

  • 1 ABIVAX, 1919 route de Mende, 34293, Montpellier Cedex 5, France. noelie.campos@igmm.cnrs.fr.
  • 2 Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicin, University of Zurich, University Hospital, Raemistrasse 100, 8091, Zurich, Switzerland. Renier.Myburgh@usz.ch.
  • 3 ABIVAX, 1919 route de Mende, 34293, Montpellier Cedex 5, France. aude.garcel@igmm.cnrs.fr.
  • 4 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. audrey.vautrin@igmm.cnrs.fr.
  • 5 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. laure.lapasset@igmm.cnrs.fr.
  • 6 Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicin, University of Zurich, University Hospital, Raemistrasse 100, 8091, Zurich, Switzerland. Erika.Schlaepfer@usz.ch.
  • 7 Institut Curie, CNRS UMR9187, INSERM U1196, Centre universitaire, Bâtiment 110, 15 rue Georges Clémenceau, 91405, ORSAY CEDEX, France. florence.mahuteau@curie.fr.
  • 8 ABIVAX, 1919 route de Mende, 34293, Montpellier Cedex 5, France. romain.najman@curie.fr.
  • 9 ABIVAX, 1919 route de Mende, 34293, Montpellier Cedex 5, France. Pauline.Fornarelli@curie.fr.
  • 10 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. ktantale@igmm.cnrs.fr.
  • 11 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. Eugenia.Basyuk@igmm.cnrs.fr.
  • 12 Plate-forme de Protéomique Fonctionnelle (FPP) IGF, UMR 5203 CNRS - INSERM U661- UM, 141 rue de la Cardonille (pièce 029), 34094, Montpellier CEDEX 05, France. martial.seveno@fpp.cnrs.fr.
  • 13 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. julian.venables2@newcastle.ac.uk.
  • 14 Université de Montpellier, UFR Pharmacie, 15 Avenue Charles Flahault, 34000, Montpellier, France. bernard.pau4@orange.fr.
  • 15 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. edouard.bertrand@igmm.cnrs.fr.
  • 16 McGill AIDS Center, Lady Davis Institute - Jewish General Hospital, Montréal, QC, Canada. mark.wainberg@mcgill.ca.
  • 17 Division of Infectious Diseases and Hospital Epidemiology Department of Internal Medicin, University of Zurich, University Hospital, Raemistrasse 100, 8091, Zurich, Switzerland. roberto.speck@usz.ch.
  • 18 ABIVAX, 1919 route de Mende, 34293, Montpellier Cedex 5, France. Didier.Scherrer@abivax.com.
  • 19 Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS UMR 5535, 1919 route de Mende, 34293, Montpellier Cedex 5, France. jamal.tazi@igmm.cnrs.fr.
PMID: 25889234 DOI: 10.1186/s12977-015-0159-3
Abstract

Background: Current therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need for new drugs, in particular those acting through new and as yet unexplored mechanisms of action to achieve HIV Infection cure. We took advantage of the unique feature of proviral genome to require both activation and inhibition of splicing of viral transcripts to develop molecules capable of achieving long lasting effect on viral replication in humanized mouse models through inhibition of Rev-mediated viral RNA biogenesis.

Results: Current HIV therapies reduce viral load during treatment but titers rebound after treatment is discontinued. We devised a new drug that has a long lasting effect after viral load reduction. We demonstrate here that ABX464 compromises HIV replication of clinical isolates of different subtypes without selecting for drug resistance in PBMCs or macrophages. ABX464 alone, also efficiently compromised viral proliferation in two humanized mouse models infected with HIV that require a combination of 3TC, Raltegravir and Tenofovir (HAART) to achieve viral inhibition in current protocols. Crucially, while viral load increased dramatically just one week after stopping HAART treatment, only slight rebound was observed following treatment cessation with ABX464 and the magnitude of the rebound was maintained below to that of HAART for two months after stopping the treatment. Using a system to visualize single HIV RNA molecules in living cells, we show that ABX464 inhibits viral replication by preventing Rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm and by interacting with the Cap Binding Complex (CBC). Deep sequencing of viral RNA from treated cells established that retained viral RNA is massively spliced but importantly, normal cellular splicing is unaffected by the drug. Consistently ABX464 is non-toxic in humans and therefore represents a promising complement to current HIV therapies.

Conclusions: ABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells including reservoirs and it is therefore a promising drug toward a functional cure of HIV.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100870
    99.61%, HIV-1抑制剂
    HIV
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z